• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

The TRITON Study is Up and Enrolling for PAH

September 1, 2016 By Dr. Jeremy Feldman

PAH researchNew Study Comparing Medication Combinations in Treatment of Pulmonary Arterial Hypertension

Actelion Pharmaceutics has undertaken an important new study that compares two medications versus three medications in patients that are newly diagnosed with PAH. Currently we can say with confidence that most patients do better when treated initially with an endothelin receptor antagonist such as Letairis combined with Adcirca (these are results from the AMBITION Study).  However, we have some recent data from the GRIPHON Study that suggest that adding a third agent (Uptravi) may improve outcomes further.  However, the GRIPHON Study added Uptravi to patients already being treated with one or two medications.  In contrast, this new study compares the combination of Opsumit plus Adcirca to the combination of Opsumit plus Adcirca plus Uptravi.

Why is this study important?  Each PAH medication is expensive and has side effects.  We are not yet sure if it is best to wait for patients to achieve a maximal response to two treatments and then consider adding a third agent or if early addition of a third agent improves outcomes.  The key to answering this question is that newly diagnosed patients that are interested in research should seek out study sites prior to beginning any treatment for PAH other than diuretics.  Patients that participate in this research study will receive their PAH medications for free as part of the study.

The primary outcome measure of this study is change in pulmonary vascular resistance after 26 weeks of therapy.  Patients must have a baseline right heart catheterization and then a repeat right heart catheterization at 26 weeks.  Other study endpoints include exercise capacity and BNP.

We are excited to participate in this study.  Interested patients can find local study centers by visiting clinicaltrial.gov

Filed Under: Pulmonary Hypertension Treatments

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

Disability placard for pulmonary hypertension patients

Handicap Placard for PH patients

By Dr. Jeremy Feldman

Pulmonary arterial hypertension is a rare and debilitating disease that affects the blood vessels of the lungs.  Many PH

PAH Expert talking with PH patient

Second Opinions

By Dr. Jeremy Feldman

I can’t tell you how frequently my patients ask if their doctor will be offended if the patient goes to a different

good news in pah

 

Disclaimer

Recent Blog Posts

  • Sotatercept Coming Soon January 10, 2023
  • Why Abortion Matters to PAH Patients May 3, 2022
  • Aerovate and Inhaled Imatinib February 13, 2022

Categories

Archives